Vertex Stock Rose From Under $40 to Over $500. Jeff Leiden Says It Started With 1 Decision
Alpha Vantage · Inc.com · · AI-summarised by FinFlash
Jeff Leiden, the former CEO of Vertex Pharmaceuticals, transformed the company from a struggling entity with stock under $40 to a biotech leader trading above $500. His strategy involved focusing on validated drug targets and fostering a team-oriented culture where leadership openly debated issues. This approach led to significant advancements, particularly in treatments for cystic fibrosis.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.